Most Anticipated
Most Anticipated #ASH26 Abstracts
Plasma cell disorders, myeloma and AL amyloidosis: the full 11-post preview thread from Samer Al Hadidi, MD,MS,FACP (@HadidiSamer), UT Southwestern, posted 2026-11-11. Each post is shown verbatim and in full, in his own numbering. Abstract data are pre-meeting and may change at presentation.
Swipe →
1/11
Open the full thread on X ↗
My top @ASH_hematology #ASH26 abstracts for plasma cell disorders including myeloma and AL amyloidosis #mmsm @utswcancer
1️⃣MonumenTAL-6: Tec+Tal and Tal+Pom vs EPd/PVd ➡️Phase III, RRMM after 1–4 prior lines, all exposed to anti-CD38 and lenalidomide (80% anti-CD38-refractory)
➡️n=838; median FU: 13.4 mo
➡️Tec+Tal improved PFS HR 0.11; 12-mo PFS 89% vs 30%) and OS (HR 0.38; 12-mo OS 91% vs 80%). Tal+Pom also better than control arm (PFS HR 0.27, OS HR 0.55).
🛑Grade 3/4 infections were 312% with Tec+Tal vs 25% with control (92% of patients needed IVIG), ICANS 6%, taste changes 76% and weight loss 41% (Only 6% stopped treatment for AEs)
Time limited therapy with dual targeting in pts after anti-CD38/len failure
👁 900
❤ 14
🔁 7
2/11
My top @ASH_hematology #ASH26 abstracts for plasma cell disorders including myeloma and AL amyloidosis #mmsm @utswcancer
2️⃣MagnetisMM-5: elranatamab vs DPd
➡️phase III, RRMM after 1–4 prior lines (72% len-refractory, only 6% had prior anti-CD38)
➡️n=497; median FU ~ 32 mo
➡️elranatamab improved PFS (HR 0.56; median not reached vs 27 mo, 36-mo PFS 64% vs 41%). OS is still immature.
🛑Grade ≥3 infections were similar (44% vs 41%) indicating high risk of infection in all RRMM but really high in control arm.
🛑Elra+Dara arm: 36-mo PFS 75%, but grade ≥3 infections of 54%.
In patients who is anti-CD38 naive, tec-dara data looks better with improved OS already reported.
👁 234
❤ 0
🔁 0
3/11
My top @ASH_hematology #ASH26 abstracts for plasma cell disorders including myeloma and AL amyloidosis #mmsm @utswcancer
3️⃣iMMagine-1: Anito-cel
➡️registrational phase II, RRMM 4th line or later
➡️ n=117; median FU 18 mo
➡️ORR 96%, CR/sCR 75%, MRD negative at 10⁻⁵ 95%. 24-mo PFS 58% and 24-mo OS 84%
🛑CRS 86%, almost all grade 1–2 (one grade 5). ICANS 8% (one grade 3). Grade ≥3 infections only 9%
➡️No parkinsonism, cranial nerve palsy, GBS, IEC-enterocolitis or secondary T-cell malignancy
Short follow up and relapses already occurring in ~ half of patients indicating likely lower efficacy than Cilta Cel though with no safety signal with short follow up
The ASH 2026 iMMagine-1 abstract uses a January 5, 2026 cutoff, only about 3 months after the ASH 2025 cutoff
👁 199
❤ 0
🔁 0
4/11
My top @ASH_hematology #ASH26 abstracts for plasma cell disorders including myeloma and AL amyloidosis #mmsm @utswcancer
4️⃣EXCALIBER-RRMM: Iberdomide-Dd vs DVd
➡️ Phase III RRMM after 1–2 prior lines, not anti-CD38- or bortezomib refractory
➡️median follow-up 15.7 mo, MRD-negative CR was 41% vs 21% (OR 2.75). MRD-negative CR lasting ≥12 months was 18.8% vs 6.6%. PFS press release: 42 months with Iberdomide-Dd vs 20 months with DVd (HR 0.49)
🛑Grade 3/4 neutropenia very high (84% vs 11%), Grade 3/4 infections were 39% vs 22%.
Good to see improvement of PFS, however BCMA therapies should be used prior given OS benefit
👁 94
❤ 0
🔁 0
5/11
My top @ASH_hematology #ASH26 abstracts for plasma cell disorders including myeloma and AL amyloidosis #mmsm @utswcancer
5️⃣IEC-Enterocolitis after cilta-cel (US Myeloma Immunotherapy Consortium)
➡️Commercial cilta-cel, n=1,793 across 23 sites.
➡️Incidence: 3.0% (55 cases), rising each year from 1.8% (2022) to 3.9% (2025) as recognition improves. Median onset was day 96.
🛑No predictors. It was associated with higher odds of other toxicities( parkinsonism and cranial nerve palsy)
Important data given the safety signal. 56% of affected patients died, 29 of 31 without myeloma progression, and 12-mo non-relapse mortality was 51%
👁 96
❤ 2
🔁 0
6/11
My top @ASH_hematology #ASH26 abstracts for plasma cell disorders including myeloma and AL amyloidosis #mmsm @utswcancer
6️⃣ NEXICART-2: NXC-201 BCMA CAR-T in AL amyloidosis
➡️ Phase I/II, R/R AL amyloidosis, 62% cardiac involvement;
➡️ n=45, median FU: 9 mo
➡️Free light chains normalized in 96% at a median of 7 days, CR was 100% (16/16) in patients followed >12 months, and 96% of the rest are MRD-negative. Organ responses were 100% cardiac (9/9) and 100% renal (11/11). NT-proBNP fell by a median 57% and proteinuria by 91%.
There was no neurotoxicity of any kind and no treatment-related infections
🛑 Grade 3/4 neutropenia was 82%.
👁 90
❤ 0
🔁 0
7/11
My top @ASH_hematology #ASH26 abstracts for plasma cell disorders including myeloma and AL amyloidosis #mmsm @utswcancer
7️⃣BMS-986453: Dual BCMA×GPRC5D CAR-T
➡️ phase I, RRMM after ≥3 prior lines (median 4), 60% prior BCMA therapy, 17% prior BCMA and GPRC5D; ➡️n=58; median FU ~ 1 yr
➡️Efficacy at 75–150M dose: ORR 94% (CR 71%), and 89% even after prior BCMA therapy. In naïve patients: ORR 100%, CR 88%, MRD-negative at 10⁻⁶ 100%, 12-mo PFS 93% (62% overall).
🛑CRS 78% (one grade 5, at 300M), ICANS 3%, infections 52% (21% grade ≥3). GPRC5D on-target/off-tumor effects in 50% (nails 36%, oral 34%, skin 19%)
Nice to see data on dual targeting CAR-T
👁 92
❤ 0
🔁 0
8/11
My top @ASH_hematology #ASH26 abstracts for plasma cell disorders including myeloma and AL amyloidosis #mmsm @utswcancer
8️⃣TALisman: prophylaxis for talquetamab oral toxicity ➡️phase II, randomized, RRMM starting talquetamab; arms were no prophylaxis or dexamethasone mouthwash, pregabalin or clonazepam
➡️n=70
🛑Prophylaxis appears to make things worse. Severe dysgeusia on the objective taste test (WETT) was 56% with no prophylaxis vs 86–100% with any of the three.
🛑Dexamethasone mouthwash added the most harm (oral mucositis 33% vs 7–13%, dysphagia 40%, thrush) and delayed recovery: 33% improved by month 3 vs 57–59% in the other arms.
Important since we need to change practice offering such supportive therapies, patients taste usually improves by ~ 3 mo
👁 89
❤ 0
🔁 0
9/11
My top @ASH_hematology #ASH26 abstracts for plasma cell disorders including myeloma and AL amyloidosis #mmsm @utswcancer
9️⃣ CaMMouflage: CB-011, allogeneic CRISPR-edited BCMA CAR-T
➡️Phase I, RRMM after ≥3 prior lines (median 4), n=48.
➡️At the recommended dose (higher-dose cyclophosphamide lymphodepletion plus 450M cells) in BCMA-naïve patients (n=12): ORR 92%, ≥CR 83%, MRD-negative 91%.
🛑No GvHD. Infections 49% (17% grade ≥3), prolonged grade ≥3 cytopenias 35%, CRS 34% and IEC-HS 9%. There was one grade 4 GBS and four grade 5 events
It is proof that an off the shelf CAR-T can work, though with infection and cytopenia burden
👁 89
❤ 0
🔁 0
10/11
My top @ASH_hematology #ASH26 abstracts for plasma cell disorders including myeloma and AL amyloidosis #mmsm @utswcancer
1️⃣0️⃣Frontline teclistamab in Mayo stage IIIB AL amyloidosis
➡️Phase II, newly diagnosed Mayo stage IIIB AL amyloidosis,teclistamab was given alone for 6 cycles (60 mg fixed dose after step-up). All had cardiac involvement and 41.7% renal involvement. Median NT-proBNP was 18,020 ng/L and median dFLC 344 mg/L.
➡️n=24, median FU: 4.0 mo
➡️ Fast responses: median 13 days to first response and 36 days to best response. At 1 month, ≥VGPR was 77.3% (CR 59.1%). Best cardiac response was 54.5% (27.3% ≥VGPR).
🛑CRS was 42%, all grade 1–2 except one grade 3, and there was no ICANS.
🛑High mortality: ~ 1/3 (8/24). Six died of progressive heart failure and 2 of infection. 5 died within 3 months,
first prospective frontline bispecific study in stage IIIB AL. Clearing the light chain within about 2 weeks is the right goal in a disease where the heart deteriorates before slower regimens can work but concerning to see still high % of early cardiac deaths indicating that hematologic speed alone is not enough
👁 134
❤ 0
🔁 0
11/11
My top @ASH_hematology #ASH26 abstracts for plasma cell disorders including myeloma and AL amyloidosis #mmsm @utswcancer
Few other studies, very small, like mRNA-2808 (in vivo trispecific BCMA/GPRC5D/FcRH5 T-cell engagers) is novel, but n=12 with 4 responses after a median of 10 prior lines. Dysgeusia was 58%, hand-foot syndrome 42% and CRS 42% (all grade 1) and other small studies will talk about in the meeting
Looking for great meeting
End 🧵
👁 110
❤ 0
🔁 0
More physician preview lists
Other hematologists sharing the abstracts they plan to watch, ranked by reach. Text is verbatim from each post.
🩸 #ASH26 | #AML Abstracts to Watch (Oral)
My current list of 11 AML abstracts to watch at #ASH2026 👇 #leusm
A mix of potentially practice-changing frontline trials, menin inhibitors, MRD, and novel approaches in both younger and older patients.
1️⃣ Ivosidenib + intensive chemotherapy in newly diagnosed IDH1-mutated AML
HOVON150/AMLSG29-18, phase 3
Superior event-free survival
📄 Abstract 0001, Press Program
📅 Sun Dec 13 | 7:00 AM CT
⚠️ Oral/plenary slot not yet confirmed
🔗 https://t.co/HAiAem9IzK
2️⃣ Gilteritinib vs midostaurin in newly diagnosed FLT3-mutated AML
Subgroup analysis from HOVON156/AMLSG28-18/pasha
📄 Abstract 56 | Session 615
📅 Sat Dec 12 | 9:30 AM
📍 Great Hall BC
🔗 https://t.co/vnNwomzMZ7
3️⃣ Bleximenib in R/R AML with KMT2A rearrangements or NPM1 mutations
Topline results from phase 2 CAMELOT-1
📄 Abstract 661 | Session 616
📅 Sun Dec 13 | 4:30 PM
📍 Hall B
🔗 https://t.co/Das1necevM
4️⃣ Cladribine + LDAC + venetoclax vs intensive chemotherapy (7+3)
Patients ≥60 years with newly diagnosed AML
📄 Abstract 57 | Session 615
📅 Sat Dec 12 | 9:30 AM
📍 Great Hall BC
🔗 https://t.co/vuvS9OfmdF
5️⃣ Can we stop HMA + venetoclax?
Discontinuation of hypomethylating agent + venetoclax in newly diagnosed AML with undetectable MRD
📄 Abstract 1009 | Session 617
📅 Mon Dec 14 | 4:30 PM
📍 Great Hall AD
🔗 https://t.co/MiP4Z7F5BL
6️⃣ Sonrotoclax + azacitidine across ELN 2024 genetic risk groups
Treatment-naive AML unfit for intensive chemotherapy
📄 Abstract 60 | Session 615
📅 Sat Dec 12 | 9:30 AM
📍 Great Hall BC
🔗 https://t.co/gU3WGMcyAm
7️⃣ Venetoclax + 3-day multi-frequency decitabine vs AZA + VEN
Older adults with newly diagnosed AML, updated randomized results
📄 Abstract 1012 | Session 617
📅 Mon Dec 14 | 4:30 PM
📍 Great Hall AD
🔗 https://t.co/L7cHhkZ4IF
8️⃣ Whole-genome-informed AML MRD testing
Prospective multicenter validation, MEASURE
📄 Abstract 390 | Session 619
📅 Sat Dec 12 | 4:00 PM
📍 Great Hall AD
🔗 https://t.co/XPb38cdFAW
9️⃣ VEN + AZA vs daunorubicin + cytarabine induction
Young adults with ELN adverse-risk AML, phase 2b
📄 Abstract 1010 | Session 617
📅 Mon Dec 14 | 4:30 PM
📍 Great Hall AD
🔗 https://t.co/T8URfhrzzg
🔟 Ziftomenib + gilteritinib in R/R NPM1- and FLT3-co-mutated AML
First results from phase 1 KOMET-008
📄 Abstract 66 | Session 617
📅 Sat Dec 12 | 9:30 AM
📍 Great Hall AD
🔗 https://t.co/nTnyI2myj8
11/12
1️⃣1️⃣ FLAI-G frontline in younger FLT3-mutated AML
Fludarabine + high-dose cytarabine + idarubicin + gilteritinib
First interim analysis, phase 2 GIMEMA AML2924
📄 Abstract 903 | Session 617
📅 Mon Dec 14 | 2:45 PM
📍 Great Hall BC
🔗 https://t.co/OwFJZBjAnr
Lots to watch at #ASH26 in AML.
Particularly interested in the randomized frontline data, evolving role of menin inhibition, MRD-guided treatment decisions, and whether lower-intensity approaches can continue challenging conventional intensive chemotherapy.
Which AML abstracts are on your must-see list?
#AML #Leukemia #ASH26
👁 5.9K
❤ 79
🔁 23
🧬 CAR-T abstracts I won’t miss at #ASH26!
My 10 picks across myeloma and lymphoma—from longer follow-up and earlier-line treatment to dual targeting, allogeneic platforms, and CAR-T cells generated in vivo.
The questions I’ll be watching:
🔹 Durability: How long do remissions last—and how much time can patients spend free of treatment?
🔹 Earlier treatment: Which patients benefit most from moving CAR-T forward?
🔹 Dual targeting: Can BCMA × GPRC5D or CD19/CD20 targeting reduce relapse?
🔹 Safety: Can we prevent delayed neurotoxicity while preserving disease control?
🔹 Access: Can allogeneic and in vivo approaches make CAR-T available to more patients?
Response rates attract attention. Durability, safety, patient selection, and study design determine clinical value. Small cohorts, subgroup analyses, and historical comparisons deserve careful interpretation.
These are my current picks; late-breaking abstracts may add more!
🎺 Jazz, crawfish, Hurricanes—and plenty of CAR-T discussion.
See you in New Orleans!
#ASH26 #CART #MultipleMyeloma #Lymphoma #HemeTwitter
👁 4.4K
❤ 55
🔁 16
More to watch at #ASH26! 📅 My schedule is attached.
Thank you for flagging two important omissions from my preview:
🔹 MonumenTAL-6: Phase III Tec–Tal and Tal–Pom—PFS and OS benefits versus EPd/PVd. Major results, with safety and longer follow-up essential to interpretation.
🔹 AQUILA: Final survival analysis in the enrolled high-risk SMM population—7-year OS 87.8% vs 78.7% with daratumumab versus monitoring. Important findings to examine alongside risk definitions and treatment after progression.
Two additional highlights:
🔹 PERSEUS: Long-term MRD outcomes and MRD-guided daratumumab maintenance discontinuation.
🔹 MajesTEC-5, Arm G: Early results with ramantamig, a BCMA × GPRC5D × CD3 trispecific, plus daratumumab/lenalidomide in transplant-eligible, newly diagnosed MM, followed by ramantamig/daratumumab maintenance without planned ASCT. This is a separate cohort from the original teclistamab-based cohorts incorporating ASCT.
An increasingly crowded—and exciting—myeloma agenda in New Orleans! 🎷🦞🍹
📅 SEE THE SCHEDULE BELOW ⬇️
Our selected abstracts, dates, times, and locations—all times CST (New Orleans local time).
Dr. Fun + G
#MultipleMyeloma #mmsm #HemeTwitter
👁 1.7K
❤ 15
🔁 7
🩸 #ASH26 | #BMT Abstracts to Watch
My current list of key allogeneic hematopoietic cell transplantation abstracts to watch at #ASH2026 👇
A mix of potentially practice-changing GVHD prevention strategies, donor selection, conditioning, MRD, and emerging transplant platforms. https://t.co/xBEZ58mNjp
👁 1.4K
❤ 16
🔁 4
Exciting news in MCL!
Zanubrutinib + rituximab in 1L transplant-ineligible MCL shows promising results in MANGROVE (interim PFS HR 0.57 vs BR).
Looking forward to seeing the full data at #ASH26! https://t.co/IgRtaIcuWI
👁 682
❤ 11
🔁 2
Conference Buzz
Top Themes Ahead of ASH 2026
Most-discussed topics across 144 curated tweets from 56 hematologists, researchers and hematology organizations. Tap any card to see the tweets.
25
Safety: CRS, ICANS, Infections & IEC
18.8K impressions
tap to see tweets
24
Chemo-Free Frontline (BTKi / Venetoclax)
35.3K impressions
tap to see tweets
17
Bispecific & Trispecific T-Cell Engagers
14.7K impressions
tap to see tweets
17
Precursor States: MGUS, Smoldering & CHIP
17.6K impressions
tap to see tweets
16
CAR-T: In Vivo, Allogeneic & Dual-Target
14.9K impressions
tap to see tweets
14
MRD & Response Depth
15.6K impressions
tap to see tweets
13
Targeted Therapy in Myeloid Disease
20.4K impressions
tap to see tweets
13
Transplant & GVHD
15.9K impressions
tap to see tweets
11
AL Amyloidosis
2.1K impressions
tap to see tweets
11
Trainees, Awards & Mentorship
11.5K impressions
tap to see tweets
9
Classical Hematology: ITP, SCD & Thrombosis
7.7K impressions
tap to see tweets
3
AI, Data & Digital Tools
651 impressions
tap to see tweets
